IDH1 and glioma: However, the fact that neoantigen derived from mutant IDH1 can promote anti-tumor CD4+ T-cells and antibody responses in glioma together with the ability of RT to expose neoantigens, suggest that IDH1 mutated GBM patients might better respond to the RT-IT combinations as opposed to patients with wild-type IDH1 tumors (117).